Novel Therapeutic Targets in Liver Fibrosis
Novel Therapeutic Targets in Liver Fibrosis
A series of transgenic and knockout mouse models to study this process and are available to collaborate on their ongoing research. Results show that the inflammatory response to liver injury involves a cascade of cytokines including the release of IL-17A
San Diego, CA, United States
Overview Comments Tagged publications

Background

Liver fibrosis often results from chronic liver pathologies, increasing the risk of cancer and even death by liver failure. Except for transplantation of the liver in advanced cases, current treatment for liver fibrosis is very limited although studies are underway to determine the mechanisms of fibrogenesis. New therapies will depend on learning the cellular events of fibrosis and finding druggable targets in those signaling pathways.


State Of Development

Physicians at UC San Diego are testing new antibodies and compounds directed against novel drug targets they identified in the progression of liver fibrosis. They have developed a series of transgenic and knockout mouse models to study this process and are available to collaborate on their ongoing research. Their results show that the inflammatory response to liver injury involves a cascade of cytokines including the release of IL-17A which activates quiescent liver cells to progress into a profibrogenic state. The process occurs through TGF-β1 (transforming growth factor-beta1) and Stat3 (signal transducer and activator of transcription 3) mediated events. These results not only promise new applications for existing anti-IL-17 compounds, but also present new target opportunities to screen for anti-fibrosis therapeutics in the IL-17 and Stat3 signaling cascades.


Related Materials

No comments.
No tagged publications.

Similar innovations

Back
or
Back
Back
or
Back
Back
or
Back
Back
or
Back
← Previous Next → 1 2 3 4 Last
Showing 1-4 from 48

Send Us a Message